CJC-1295 occupies an unusual position: it is not a supplement, not an approved drug, and not quite an illegal substance. It is sold as a research chemical, marketed as an anti-ageing peptide, and administered by people using dosing arithmetic they found in a forum. Understanding it properly means separating three things that get blurred together — what it does biologically, what it has been shown to achieve, and what regulators have said about it.

What it is

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone, the signal the hypothalamus sends to tell the pituitary to release growth hormone. It is modified to resist the enzyme that normally breaks GHRH down within minutes, which extends its action from minutes to days.

Two versions circulate under the same name, and the distinction matters. The original CJC-1295 included a drug affinity complex — a chemical group that binds it to albumin in the blood, extending its half-life to about a week. What is usually sold now is the version without that modification, often labelled CJC-1295 no-DAC or modified GRF (1-29), with a half-life closer to thirty minutes. Sellers frequently do not specify which they are shipping.

What human studies actually measured

There is real human data, and it is narrower than the marketing suggests. The published trials measured hormone levels, not outcomes.

The hormone response

A 2006 study in healthy adults found single doses raised growth hormone levels two- to tenfold for six days, with IGF-1 rising 1.5- to threefold and staying elevated for up to eleven days. Repeated dosing sustained the elevation. This is the finding that every marketing page cites, and it is accurate.

What was not measured

None of these studies followed body composition, muscle mass, fat mass, sleep architecture, skin thickness, injury healing or athletic performance. The chain of reasoning from "raises IGF-1" to "improves body composition" is an inference, not a result. Growth hormone replacement in people with genuine deficiency does change body composition — but that is a different population with a different problem, treated with a different drug under medical supervision.

The safety signal

Development of the DAC version was halted after a death in a clinical trial. The event was not conclusively attributed to the drug, but the programme did not continue. That history rarely appears alongside the hormone-elevation data.

Where regulators stand

CJC-1295 has no marketing approval anywhere. In 2023, following its review of substances nominated for compounding, the FDA placed it in Category 2 — bulk drug substances that present significant safety risks. The agency's stated concerns were the potential for immunogenicity, the absence of adequate safety data, and the lack of any established effective dose.

The World Anti-Doping Agency prohibits it at all times as a growth hormone secretagogue. Products sold as research chemicals rely on a "not for human consumption" label, which is a legal posture rather than a claim about what the buyer will do with them.

The problem with research-grade vials

This is where the practical risk sits, and it is separate from the pharmacology.

Identity and purity

Independent testing of peptides sold online has repeatedly found products that do not match their labels — wrong quantity, degraded peptide, or a different compound entirely. There is no regulatory requirement for any of it to be true.

Sterility

These are injected products supplied as lyophilised powder for the buyer to reconstitute. Nothing guarantees the vial was filled under sterile conditions, and reconstitution at a kitchen counter adds its own contamination risk.

Dose

There is no established effective or safe dose, because no dose-finding trial was completed for any therapeutic use. Protocols circulating online are conventions, not evidence.

Plausible risks of raising growth hormone long term

Even assuming a pure product at a sensible dose, sustained elevation of growth hormone and IGF-1 is not obviously benign. Known effects of growth hormone excess include fluid retention, joint pain, carpal tunnel syndrome and reduced insulin sensitivity. Elevated IGF-1 is associated in observational research with higher risk of some cancers, which is a signal rather than a proven causal relationship but is the reason growth hormone is prescribed carefully even where it is indicated.

None of this is a prediction about any individual. It is the reason a drug that raises these hormones for days at a time would normally require trials before being sold to healthy adults.

If your actual goal is body composition or recovery

Most people considering peptides are trying to solve something specific. The interventions with real evidence for those goals are unglamorous and well established.

  • Muscle and strength at midlife: resistance training two or three times weekly plus protein at 1.2 to 1.6 g per kg. Our guide to muscle loss in menopause covers why this matters more after 50.
  • Sleep quality: the causes worth excluding are sleep apnea, night sweats and alcohol — see menopause insomnia.
  • Fat loss: the approved options with outcome data are the GLP-1 drugs, which have trials measuring weight rather than hormone levels.
  • Skin: sun protection and topical retinoids have the evidence; see skin at menopause.

None of these are as interesting as a peptide. All of them have been measured against the outcome you care about.

What we are not telling you

We do not publish dosing protocols, reconstitution instructions or sourcing guidance for unapproved peptides, and that is deliberate. There is no established safe dose to give, no way to verify what is in a vial bought online, and no monitoring in place if something goes wrong. If you are considering this, the useful conversation is with a clinician who can look at what you are actually trying to fix.